Literature DB >> 23100384

[Effect of Gorei-san with tranexamic acid for preventing recurrence of chronic subdural hematoma].

Yukihiro Wakabayashi1, Masanori Yamashita, Tomoshige Asano, Akira Yamada, Hiroyuki Kenai, Yayoi Kondoh, Yuzo Hori, Hirofumi Nagatomi.   

Abstract

OBJECT: Chronic subdural hematoma is often seen in elderly patients. One burr hole surgery with subdural drainage has been performed and prognosis is good, but the recurrence rate is still about 10%. To prevent the recurrence, we used Kampo-medicine Gorei-san with tranexamic acid after surgery. The purpose of this study is to investigate if the recurrence is able to prevent by using these drugs.
METHODS: From January 2008 to December 2010, 199 consecutive cases with chronic subdural hematoma were examined at Nagatomi Neurosurgical Hospital. Patients were divided into four groups according to the administered drugs; Gorei-san, tranexamic acid, Gorei-san with tranexamic acid and no drug groups. The recurrence rate was compared between each group. The chi-square test was performed as a statistical analysis.
RESULTS: In all patients, the mean age was 77.7±10.5 years. There were 140 males and 59 females. Overall recurrence rate was 7.0%. Each recurrence rate was 8.3% in the Gorei-san administration group, and 10.9% in the tranexamic acid group, and 2.9% in Gorei-san with tranexamic acid group, and 5.7% in the no-drug group. There was no significant difference between the four groups in statistical analysis.
CONCLUSIONS: Gorei-san with the tranexamic acid administration group had the minimum recurrence. There was no significant difference but these drugs would be preventable recurrence of chronic subdural hematoma. We need to accumulate more cases as a prospective study in the future.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23100384

Source DB:  PubMed          Journal:  No Shinkei Geka        ISSN: 0301-2603


  8 in total

Review 1.  Usefulness of interventional embolization of the middle meningeal artery for recurrent chronic subdural hematoma: Five cases and a review of the literature.

Authors:  Akira Tempaku; Shigeru Yamauchi; Hidetoshi Ikeda; Nobuyuki Tsubota; Hironori Furukawa; Daisuke Maeda; Kimito Kondo; Akimasa Nishio
Journal:  Interv Neuroradiol       Date:  2015-05-26       Impact factor: 1.610

Review 2.  Chronic Subdural Hematoma in Elderly Patients: Is This Disease Benign?

Authors:  Masaaki Uno; Hiroyuki Toi; Satoshi Hirai
Journal:  Neurol Med Chir (Tokyo)       Date:  2017-06-26       Impact factor: 1.742

3.  Effectiveness of Goreisan in Preventing Recurrence of Chronic Subdural Hematoma.

Authors:  Shunsaku Goto; Kyozo Kato; Taiki Yamamoto; Shinji Shimato; Tomotaka Ohshima; Toshihisa Nishizawa
Journal:  Asian J Neurosurg       Date:  2018 Apr-Jun

4.  Effect of Goreisan, a traditional Japanese Kampo medicine, on postoperative nausea and vomiting in gynecological patients.

Authors:  Keiko Kume; Yusuke Kasuya; Makoto Ozaki
Journal:  JA Clin Rep       Date:  2017-09-29

Review 5.  The Role of Medical Treatment in Chronic Subdural Hematoma.

Authors:  Amit Kumar Thotakura; Nageswara Rao Marabathina
Journal:  Asian J Neurosurg       Date:  2018 Oct-Dec

Review 6.  Oreongsan, an herbal medicine prescription developed as a new alternative treatment in patients with chronic subdural hematoma: a narrative review.

Authors:  Seungwon Kwon; Chul Jin; Ki-Ho Cho
Journal:  Integr Med Res       Date:  2018-11-24

7.  A Prospective Randomized Study on the Preventive Effect of Japanese Herbal Kampo Medicine Goreisan for Recurrence of Chronic Subdural Hematoma.

Authors:  Naoaki Fujisawa; Soichi Oya; Shinsuke Yoshida; Tsukasa Tsuchiya; Takumi Nakamura; Masahiro Indo; Toru Matsui
Journal:  Neurol Med Chir (Tokyo)       Date:  2020-11-19       Impact factor: 1.742

8.  Tranexamic acid to prevent operation in chronic subdural haematoma (TORCH): study protocol for a randomised placebo-controlled clinical trial.

Authors:  S Immenga; R Lodewijkx; Y B W E M Roos; S Middeldorp; C B L M Majoie; H C Willems; W P Vandertop; D Verbaan
Journal:  Trials       Date:  2022-01-18       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.